Testosterone therapy and future fertility: decide before the first prescription

If future biological fatherhood matters, discuss it before starting testosterone therapy. Exogenous testosterone can suppress the hormonal signals needed for sperm production; the Endocrine Society recommends against starting testosterone in men planning fertility in the near term. That does not mean everyone who has used testosterone is permanently infertile, nor does it establish a reliable recovery time for any one person. The first decision is whether the proposed treatment and the person’s family-building timeline belong in the same plan.¹

Why a normal testosterone number is not the fertility endpoint

Prescription testosterone raises circulating testosterone from outside the body. The reproductive system also depends on signaling to the testes. External testosterone can reduce that signaling and sperm production even when a blood testosterone result appears satisfactory for symptom treatment. A testosterone lab value, a symptom score, and a semen result answer different questions. A clinic that measures only the first two has not completed a fertility conversation.¹

This is a different decision from comparing clomiphene-family medicines with testosterone. Our enclomiphene-versus-clomiphene-versus-testosterone guide explains product and regulatory distinctions. It does not turn any alternative into a universal fertility-preserving prescription. The clinician must first confirm whether testosterone deficiency has been properly diagnosed, whether treatment is indicated, and what fertility goal is actually present.¹²

Make the timeline specific enough to act on

“Maybe children someday” and “trying to conceive in six months” are not equivalent clinical histories. Bring any partner timeline, previous semen results if available, prior fertility care, and a list of testosterone, anabolic steroids, or supplements already used. A practice should be able to say how it evaluates fertility plans before treatment and when it would involve a reproductive specialist. It should not offer a confident promise that fertility will remain intact or return by a particular date.

The guideline also emphasizes diagnosis: symptoms or signs compatible with testosterone deficiency and unequivocally and consistently low testosterone concentrations, with additional evaluation to understand the cause. Fertility planning does not replace that workup; it changes which treatment discussions are appropriate after it. A lab package sold as “TRT eligibility” is not a substitute for both parts of the evaluation.¹

If treatment has already started

The most common consultation failure is timing: the fertility question appears after a prescription is underway. Before treatment, there is room to ask whether semen analysis, reproductive-urology input, or another evaluation belongs in the plan. After treatment begins, the team has to interpret results in the context of an exposure that may have changed sperm production. Neither stage should be handled by promising that a different testosterone formulation—gel instead of injection, for example—removes the fertility concern. The guideline’s recommendation addresses testosterone therapy when near-term fertility is planned, not one delivery device.¹

If the person has already had a semen test, retain the dated laboratory report rather than summarizing it as “normal.” A reproductive specialist may need to know the collection date relative to testosterone or anabolic-steroid use. If no test exists, that absence is itself useful context for an honest uncertainty discussion; the prescriber should not invent a baseline.

Tell the current prescriber about a new or newly urgent pregnancy goal. Stopping or changing a prescription on the basis of an article can disrupt care and still leave the fertility question unanswered. The clinician can document what was used, consider appropriate testing and referral, and discuss uncertainty about recovery. A history of previous use is useful information, not a reason to avoid the conversation.

For a prospective clinic, ask: “How do you screen for near-term fertility plans before prescribing? If I may want biological children, who reviews that risk and where do you refer?” The answer should be clear before a consent form is signed. Treomark’s hormone-therapy directory can help compare provider access; the TRT clinic checklist covers the broader evaluation, while this guide protects the distinct fertility decision.